MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Nephros Gross Profit 2011-2026 | NEPH
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Nephros
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.4 M | 4.73 M | 5.63 M | 4.91 M | 6.08 M | 3.2 M | 2.29 M | 1.29 M | 1.06 M | 1.2 M | 842 K | 1.07 M | 868 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.4 M | 842 K | 3.2 M |
Quarterly Gross Profit Nephros
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.92 M | 2.8 M | 3.15 M | - | 2.15 M | 1.91 M | 2.19 M | - | 2.19 M | 2.08 M | 2.11 M | - | 762 K | 1.4 M | 1.05 M | - | 1.36 M | 1.28 M | 1.59 M | - | 1.22 M | 895 K | 1.49 M | - | 1.82 M | 1.37 M | 998 K | - | 952 K | 830 K | 467 K | - | 532 K | 517 K | 455 K | - | 316 K | 297 K | 295 K | - | 166 K | 358 K | 282 K | - | 316 K | 299 K | 367 K | - | 229 K | 349 K | 325 K | - | 413 K | 267 K | 311 K | - | 309 K | 203 K | 199 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.15 M | 166 K | 1.02 M |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
401 M | $ 29.85 | 1.05 % | $ 1.43 B |  USA |
 |
AngioDynamics
ANGO
|
158 M | $ 10.6 | -1.03 % | $ 433 M | USA |
 |
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M | USA |
 |
Harvard Bioscience
HBIO
|
66.1 M | $ 0.47 | -4.15 % | $ 19.9 M | USA |
 |
Alcon
ALC
|
5.74 B | $ 77.32 | -1.5 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | USA |
 |
ICU Medical
ICUI
|
822 M | $ 125.85 | -2.28 % | $ 3.1 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | USA |
 |
InfuSystem Holdings
INFU
|
62.6 M | $ 9.31 | -0.85 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
527 M | $ 113.0 | -1.46 % | $ 3.62 B | USA |
 |
Intuitive Surgical
ISRG
|
6.64 B | $ 472.16 | -1.48 % | $ 169 B | USA |
 |
The Cooper Companies
COO
|
2.68 B | $ 69.92 | -2.24 % | $ 13.9 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
239 M | $ 97.02 | -0.79 % | $ 4.7 B | USA |
 |
Becton, Dickinson and Company
BDX
|
8.29 B | $ 159.36 | -0.17 % | $ 45.8 B | USA |
 |
Haemonetics Corporation
HAE
|
749 M | $ 59.92 | 0.72 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
13.2 M | $ 6.14 | -3.0 % | $ 33.9 K | USA |
 |
Masimo Corporation
MASI
|
1 B | $ 175.49 | -0.01 % | $ 9.35 B | USA |
 |
Isoray
ISR
|
817 K | - | 0.03 % | $ 108 M | USA |
 |
Predictive Oncology
POAI
|
798 K | - | - | $ 31.1 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
6.84 M | $ 11.56 | -2.12 % | $ 28 M | USA |
 |
Repro Med Systems
KRMD
|
25.6 M | $ 4.28 | -0.7 % | $ 198 M | USA |
 |
Baxter International
BAX
|
3.38 B | $ 17.4 | -3.36 % | $ 8.93 B | USA |
 |
BioLife Solutions
BLFS
|
18.6 M | $ 18.36 | 1.16 % | $ 846 M | USA |
 |
ResMed
RMD
|
2.02 B | $ 230.84 | -0.68 % | $ 33.7 B | USA |
 |
Retractable Technologies
RVP
|
-1.03 M | $ 0.71 | 2.62 % | $ 21.3 M | USA |
 |
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | USA |
 |
Merit Medical Systems
MMSI
|
738 M | $ 69.95 | 2.61 % | $ 4.14 B | USA |
 |
Envista Holdings Corporation
NVST
|
1.49 B | $ 24.61 | -3.26 % | $ 4.13 B | USA |
 |
STAAR Surgical Company
STAA
|
182 M | $ 18.84 | 2.45 % | $ 934 M | USA |
 |
Stereotaxis
STXS
|
17.1 M | $ 1.89 | 0.27 % | $ 172 M | USA |
 |
Teleflex Incorporated
TFX
|
307 M | $ 107.32 | -0.87 % | $ 4.79 B | USA |
 |
OraSure Technologies
OSUR
|
48.2 M | $ 2.97 | -3.88 % | $ 218 M | USA |
 |
LeMaitre Vascular
LMAT
|
179 M | $ 108.06 | 1.43 % | $ 2.45 B | USA |
 |
Utah Medical Products
UTMD
|
7.1 M | $ 63.28 | 1.02 % | $ 230 M | USA |
 |
Pro-Dex
PDEX
|
19.5 M | $ 48.46 | 3.5 % | $ 159 M | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.69 | -1.47 % | $ 27.4 M |  Israel |
 |
West Pharmaceutical Services
WST
|
1.1 B | $ 235.46 | 1.89 % | $ 17 B | USA |
 |
Repligen Corporation
RGEN
|
151 M | $ 114.2 | 0.39 % | $ 6.36 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.54 | -2.2 % | $ 2.3 B | USA |
 |
STERIS plc
STE
|
2.4 B | $ 214.57 | 1.05 % | $ 21.2 B | USA |
 |
Milestone Scientific
MLSS
|
6.43 M | $ 0.28 | -3.75 % | $ 22.3 M | USA |